

STREGA Reporting Recommendations, Extended from STROBE Statement

Item	Item No	Description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and Abstract	1	(a) Indicate the study’ s design with a commonly used term in the title or the abstract.	Page1/Line4-7	Title/Paragraph1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found.	Page2/Line3-24	Background/Paragraph1,Methods/Paragraph1,Results/Paragraph1
Introduction				
Background rationale	2	Explain the scientific background and rationale for the investigation being reported.	Page3/1-48,Page4/1-51,Page5/1-49,Page6/1-14	Introduction/Paragraph13,Rationale and Knodge gap/Paragraph1
Objectives	3	State specific objectives, including any pre-specified hypotheses. (State if the study is the first report of a genetic association, a replication effort, or both.)	Page6/Line16-30	Objectives/Paragraph1
Methods				
Study design	4	Present key elements of study design early in the paper.	Page6/31-45,Page7/1-45,Page8/1-46	Metiriods and Methods/Paragraph1-10
Setting	5	Describe the setting, locations and relevant dates, including periods of recruitment, exposure, follow-up, and data collection.	Page8/Line20-46	Clinical data demonstration/Paragraph1
Participants	6	(a) Cohort study – Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up. Case-control study – Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls. Cross-sectional study – Give the eligibility criteria, and the sources and methods of selection of participants. (Give information on the criteria and methods for selection of subsets of participants from a larger study, when relevant.)	Page6/Line33-45	Data acquisition and proccession/Paragraph1-3
		(b) Cohort study – For matched studies, give matching criteria and number of exposed and unexposed. Case-control study – For matched studies, give matching criteria and the number of controls per case.	N/A,The article does not involve relevant content	N/A,The article does not involve relevant content

Variables	7	(a) Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. (b) Clearly define genetic exposures (genetic variants) using a widely-used nomenclature system. Identify variables likely to be associated with population stratification (confounding by ethnic origin).	Page7/Line1-45,Page8/Line1-46	Materials and Methods/Paragraph 2-10
-----------	---	---	-------------------------------	--------------------------------------

Data sources/ measurement	8*	(a) For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. (b) Describe laboratory methods, including source and storage of DNA, genotyping methods and platforms (including the allele calling algorithm used, and its version), error rates and call rates. State the laboratory/centre where genotyping was done. Describe comparability of laboratory methods if there is more than one group. Specify whether genotypes were assigned using all of the data from the study simultaneously or in smaller batches.	Page7/Line1-45,Page8/Line1-46	Materials and Methods/Paragraph 2-10
Bias	9	(a) Describe any efforts to address potential sources of bias. (b) or quantitative outcome variables, specify if any investigation of potential bias resulting from pharmacotherapy was undertaken. If relevant, describe the nature and magnitude of the potential bias, and explain what approach was used to deal with this.	Page8/Line20-46	Clinical data demonstration/Paragraph 1
Study size	10	Explain how the study size was arrived at.	Page6/Line33-45	Data acquisition and procession/Paragraph 1-3
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why. (If applicable, describe how effects of treatment were dealt with.)	Page7/Line1-45,Page8/Line1-46	Materials and Methods/Paragraph 2-10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding. [State software version used and options (or settings) chosen.]	Page7/Line1-45,Page8/Line1-46	Materials and Methods/Paragraph 2-10
		(b) Describe any methods used to examine subgroups and interactions.	Page7/Line1-45,Page8/Line1-46	Materials and Methods/Paragraph 2-10
		(c) Explain how missing data were addressed.	Page6/Line33-45	Data acquisition and procession/Paragraph 1-3
		(d) CopoL\$ 2\$ngλ – If applicable, explain how loss to follow-up was addressed. Cg2G-cou\$LoI 2\$ngλ – If applicable, explain how matching of cases and controls was addressed. CLo22-2Gc\$lougi 2\$ngλ – If applicable, describe analytical methods taking account of sampling strategy.	Page8/Line20-46	Clinical data demonstration/Paragraph 1

		(e) Describe any sensitivity analyses.	N/A,The article does not involve relevant content	N/A,The article does not involve relevant content
		(f) State whether Hardy-Weinberg equilibrium was considered and, if so, how.	N/A,The article does not involve relevant content	N/A,The article does not involve relevant content
		(g) Describe any methods used for inferring genotypes or haplotypes.	N/A,The article does not involve relevant content	N/A,The article does not involve relevant content
		(h) Describe any methods used to assess or address population stratification.	Page7/Line2-25	GR Correlation Analysis/ Paragraph1-2
		(i) Describe any methods used to address multiple comparisons or to control risk of false positive findings.	Page8/Line21-25	Clinical data demonstration/Paragraph1
		(j) Describe any methods used to address and correct for relatedness among subjects	N/A,The article does not involve relevant content	N/A,The article does not involve relevant content

Results				
Participants	13*	(a) Report the numbers of individuals at each stage of the study – e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed. <i>(Report numbers of individuals in whom genotyping was attempted and numbers of individuals in whom genotyping was successful).</i>	Page9/Line2-25,Page11/Line15-37	Validation of GR clinical relevance/Paragraph1,ZEB1 participates in the EMT process through its downstream SETD1B/Paragraph1
		(b) Give reasons for non-participation at each stage.	Page9/Line2-25,Page11/Line15-37	Validation of GR clinical relevance/Paragraph1,ZEB1 participates in the

				EMT process through its downstream SETD1B/Paragraph 1
		(c) Consider use of a flow diagram.	Page17/Line2-4	Flow chart of the study/Fig1
Descriptive data	14*	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders. (Consider giving information by genotype.)	Page9/Line2-25,Page11/Line15-37	Validation of GR clinical relevance/Paragraph 1,ZEB1 participates in the EMT process through its downstream SETD1B/Paragraph 1
		(b) Indicate the number of participants with missing data for each variable of interest.	N/A,The article does not involve relevant content	N/A,The article does not involve relevant content
		(c) Cohort study – Summarize follow-up time (e.g., average and total amount).	N/A,The article does not involve relevant content	N/A,The article does not involve relevant content
Outcome data	15*	Cohort study – Report numbers of outcome events or summary measures over time. [Report outcomes (phenotypes) for each genotype category over time]	N/A,The article does not involve relevant content	N/A,The article does not involve relevant content
		Case-control study – Report numbers in each exposure category, or summary measures of exposure. (Report numbers in each genotype category)	N/A,The article does not involve relevant content	N/A,The article does not involve relevant content
		Cross-sectional study – Report numbers of outcome events or summary measures. [Report outcomes (phenotypes) for each genotype category]	Page10/Line40-46,Page11/Line1-13	Key protein function validation and survival analysis/Paragraph 1
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence intervals). Make clear which confounders were adjusted for and why they were included.	Page18/Fig2,Page19/Fig3,Page27/Fig10,Page28/Fig11	Figures/Fig2,Fig3,Fig10,Fig11
		(b) Report category boundaries when continuous variables were categorized.	Page8/Line21-25	Clinical data demonstration/Para

				graph1
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period.	N/A,The article does not involve relevant content	N/A,The article does not involve relevant content
		(d) Report results of any adjustments for multiple comparisons.		
Other analyses	17	(a) Report other analyses done – e.g., analyses of subgroups and interactions, and sensitivity analyses.	Page11/Line15-37	ZEB1 participates in the EMT process through its downstream SETD1B/Paragraph 1
		(b) If numerous genetic exposures (genetic variants) were examined, summarize results from all analyses undertaken.	N/A,The article does not involve relevant content	N/A,The article does not involve relevant content
		(c) If detailed results are available elsewhere, state how they can be accessed.	Page6/Line33-45	Data acquisition and processing/Paragrapg1-3
Discussion				
Key results	18	Summarize key results with reference to study objectives.	Page14/Line1-18	Conclusion/Paragraph1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	Page13/Line18-23	Strengths and limitations/Paragraph2
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	Page13/Line24-27	Comparision with similar researches/Paragraph1
Generalizability	21	Discuss the generalizability (external validity) of the study results.	Page13/Line30-37	Implications and actions needed/Paragraph1
Other Information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based.	Page14/Line19-21	Acknowledgements /Paragraph1

From: Little J, Higgins JPT, Ioannidis JPA, Moher D, Gagnon F, et al. (2009) STrengthening the REporting of Genetic Association Studies (STREGA) —An extension of the STROBE Statement. PLoS Med 6(2): e1000022. doi:10.1371/journal.pmed.1000022

* Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Please leave this space alone as it will be supplemented by the editorial office when needed.

